The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

References

• MillsA, CrofootG, McDonaldC, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445. doi:10.1097/QAI.000000000000061825867913
   PubMed Web of Science ®Google Scholar
• RaffiF, OrkinC, ClarkeA, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75(2):226–231. doi:10.1097/QAI.000000000000134428272164
   PubMed Web of Science ®Google Scholar
• WohlD, OkaS, ClumeckN, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72(1):58–64. doi:10.1097/QAI.000000000000094026829661
   PubMed Web of Science ®Google Scholar
• KauppinenKJ, KivelaP, SutinenJ. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting. AIDS Patient Care STDS. 2019;33(12):500–506. doi:10.1089/apc.2019.023631742421
   PubMed Web of Science ®Google Scholar
• KovariH, SabinCA, LedergerberB, et al. Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: the data collection on adverse events of anti-HIV drugs study. Open Forum Infect Dis. 2016;3(1):ofw009.26925429
   PubMed Web of Science ®Google Scholar
• MandalaJ, NandaK, WangM, et al. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol. 2014;15:77. doi:10.1186/2050-6511-15-7725539648
   PubMed Web of Science ®Google Scholar
• AgarwalK, BrunettoM, SetoWK, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–681. doi:10.1016/j.jhep.2017.11.03929756595
   PubMed Web of Science ®Google Scholar
• Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Bethesda, MD: National Institute of Allergy and Infectious Diseases; 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed December 9, 2020.http://rcc.tech-res-intl.com/tox_tables.htm
   Google Scholar
• BonfantiP, MartinelliC, RicciE, et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2005;39(3):317–320. doi:10.1097/01.qai.0000164248.56722.3c15980692
   PubMed Web of Science ®Google Scholar
• Friis-MollerN, ThiebautR, ReissP, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501. doi:10.1097/HJR.0b013e328336a15020543702
   PubMedGoogle Scholar
• D’AgostinoRB, GrundyS, SullivanLM, WilsonP; Group CHDRP. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–187. doi:10.1001/jama.286.2.18011448281
   PubMed Web of Science ®Google Scholar
• AdaramoyeOA, AdewumiOM, AdesanoyeOA, FaokunlaOO, FarombiEO. Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E. J Basic Clin Physiol Pharmacol. 2012;23(2):69–75. doi:10.1515/jbcpp.2011.004222944656
   PubMedGoogle Scholar
• PeterAI, NaiduEC, AkangE, et al. Investigating organ toxicity profile of tenofovir and tenofovir nanoparticle on the liver and kidney: experimental animal study. Toxicol Res. 2018;34(3):221–229. doi:10.5487/TR.2018.34.3.22130057696
   PubMed Web of Science ®Google Scholar
• FonnerVA, DalglishSL, KennedyCE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983. doi:10.1097/QAD.000000000000114527149090
   PubMed Web of Science ®Google Scholar
• MurakamiE, WangT, ParkY, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59(6):3563–3569. doi:10.1128/AAC.00128-1525870059
   PubMed Web of Science ®Google Scholar
• LeeJ, ParkJS, RohYS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res. 2019;42(11):935–946.31571145
   PubMed Web of Science ®Google Scholar
• HuaH, ZhangZ, QianY, et al. Inhibition of the mitochondrial complex-1 protects against carbon tetrachloride-induced acute liver injury. Biomed Pharmacother. 2019;115:108948. doi:10.1016/j.biopha.2019.10894831078037
   PubMed Web of Science ®Google Scholar
• RitouEKT. In vitro modelling of the impact of TAF on cellular bioenergetics in immune cells and hepatocytes. 21st International workshop on co-morbidities and adverse drug reactions in HIV; 5–6 November 2019, 2019; Basel, Switzerland. Antivir Ther. 2019;24(S1):A100.
   Google Scholar
• LiM, ZhouL, DorseyHG, et al. Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line. Antiviral Res. 2020;183:104948. doi:10.1016/j.antiviral.2020.10494832980447
   PubMed Web of Science ®Google Scholar
• MoureR, DomingoP, Gallego-EscuredoJM, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res. 2016;132:59–65. doi:10.1016/j.antiviral.2016.05.01327216995
   PubMed Web of Science ®Google Scholar
• SpinnerCD, SchulzS, BauerU, et al. Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR study. Antivir Ther. 2018;23(7):629–632. doi:10.3851/IMP327130281025
   PubMed Web of Science ®Google Scholar
• SaxPE, ErlandsonKM, LakeJE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–1389.31606734
   PubMed Web of Science ®Google Scholar
• TaramassoL, BonfantiP, RicciE, et al. Factors associated with weight gain in people treated with dolutegravir. Open Forum Infect Dis. 2020;7(6):ofaa195. doi:10.1093/ofid/ofaa19532577427
   PubMed Web of Science ®Google Scholar
• GagliardiniR, FabbianiM, ColafigliM, et al. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017;29(5):299–307. doi:10.1080/1120009X.2016.126904028019192
   PubMed Web of Science ®Google Scholar
• CampoR, DeJesusE, BredeekUF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56(11):1637–1645. doi:10.1093/cid/cis120323362296
   PubMed Web of Science ®Google Scholar